H.C. Wainwright raised the firm’s price target on Metagenomi (MGX) to $14 from $7 and keeps a Buy rating on the shares after the company reported 16- month data for its hemophilia A program in non-human primates. The firm cites the strengthening durability for increasing its probability of success to 25% from 20%.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGX:
- Metagenomi presents updated preclinical NHP data at ASH meeting
- Metagenomi presents updated preclinical data in Hemophilia A at ASH
- Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
- Class Action Lawsuit Against Metagenomi Inc. (NASDAQ:MGX)
- Metagenomi Reports Q3 Earnings and Strategic Progress